Moreover, when prescribing IL-17 inhibitors, caution is advised for patients with clinical or subclinical inflammatory bowel disease (IBD), as these inhibitors may exacerbate IBD, requiring careful patient selection and monitoring [58]. This evidence concerns the gene IL17A and inflammatory bowel disease.